Brief description of trial (Data source: BASEC)
Cette étude de phase II a pour but de tester un nouveau médicament pas encore autorisé en Suisse, administré en association avec un traitement connu ou seul. L'objectif est de déterminer si le médicament atézolizumab, et les associations de l’atézolizumab avec le bévacizumab et/ou l’acide acétylsalicylique, montrent une activité contre le cancer des ovaires et/ou sont sans danger.
L’atézolizumab est un médicament «d’immunothérapie», qui stimule le système immunitaire de l'organisme de manière à ralentir ou arrêter la croissance tumorale en bloquant PD-L1 (Programmed Death-Ligand 1). Le bévacizumab, déjà approuvé pour le traitement de cette maladie, est un anticorps qui inhibe la formation de vaisseaux dans la tumeur en bloquant le facteur de croissance endothélial vasculaire (Vascular Endothelial Growth Factor (VEGF)). Comme certaines données laissent penser que l’acide acétylsalicylique (aspirine ou AAS) pourrait contribuer à renforcer l’efficacité de ces médicaments, nous étudions également l’ajout d’aspirine à ces médicaments. Cet essai teste la valeur de l’association d’un médicament anticancéreux immunologique, l’atézolizumab, avec le bévacizumab et/ou l’aspirine.
Update protocol v5.0: Les groupes 2 et 3 ont étés fermés prématurément en raison de la possibilité que la thérapie avec l’atezolizumab seul, avec l’aspirine/placebo, ne soit pas suffisamment efficace pour traiter votre cancer par rapport aux 3 autres traitements.
Health conditions investigated(Data source: BASEC)
Cancer de l'ovaire
Health conditions
(Data source: WHO)
Ovarian Neoplasms
Rare disease
(Data source: BASEC)
No
Intervention investigated (e.g. drug, therapy or campaign)
(Data source: BASEC)
Groupe 1: bévacizumab seul
Groupe 2: atézolizumab + placebo (closed)
Groupe 3: atézolizumab + acide acétylsalicylique (closed)
Groupe 4: bévacizumab + atézolizumab + placebo
Groupe 5: bévacizumab + atézolizumab + acide acétylsalicylique
Interventions
(Data source: WHO)
Drug: Bevacizumab;Drug: atezolizumab;Drug: acetylsalicylic acid;Drug: placebo
Criteria for participation in trial
(Data source: BASEC)
- Cancer de l'ovaire (épithélial, des trompes de Fallope, péritonéal primaire) récurrent, confirmé histologiquement, résistant au platine, de stade avancé ou métastatique
- Au moins une lésion accessible à la biopsie sans mise en danger du patient
- Traitement préalable systémique (chimiothérapie, hormonothérapie, agents biologiques et/ou vaccins) ou radiothérapie.
Exclusion criteria
(Data source: BASEC)
- Participation actuelle, récente (dans les 4 semaines avant la randomisation) ou planifiée à une étude expérimentale de médicament
- Hypercalcémie incontrôlée ou symptomatique nécessitant un traitement continu aux biphosphonates ou au dénosumab.
- Maladie symptomatique du cerveau ou leptoméningée; toute métastase cérébrale ne progressant pas depuis au moins 6 moins.
Inclusion/Exclusion Criteria
(Data source: WHO)
Inclusion Criteria:
Recurrent, histologically proven, platinum-resistant, epithelial ovarian, fallopian tube
and primary peritoneal cancer in advanced or metastatic stage. Histological diagnosis by
image guided biopsy, laparoscopy or laparotomy. Tumors diagnosed on cytology only and
borderline tumors are excluded.
At least one lesion accessible to biopsy without putting patient at risk
WHO PS: 0-2 for patients having received no more than two previous lines of therapy. WHO
PS: 0-1 for patients having received >2 previous lines of therapy
Prior chemotherapy or bevacizumab:
Any number of platinum-based chemotherapy lines are allowed but a maximum of 2 previous
non-platinum containing lines
Prior treatment with bevacizumab or other targeted agents against Vascular Endothelial
Growth Factor (VEGF) or VEGF receptor is allowed, but at least 18 weeks must have elapsed
since their last administration
Eligible patients with = 2 previous treatment lines must have been previously exposed to
bevacizumab or other targeted agents against VEGF or VEGF receptor
Patients may have had prior therapy providing the following conditions are met:
Radiation therapy: wash-out period of 14 days prior to the first study treatment;
exception: single fraction radiotherapy with the indication of pain control
Systemic anti-tumor therapy: wash-out period of 21 days prior to the first study treatment
Recovery from any toxic effects of prior therapy to = Grade 1 per the National Cancer
Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v4.03) except fatigue
or alopecia.
Exclusion criteria:
Age <18 years
Life expectancy of < 12 weeks
No adequate hematologic and end organ function
Use of acetylsalicylic acid, NSAIDs or other COX-2 inhibitors that cannot be stopped at
baseline and for the whole duration of the study.
-
Further information on trial
Date trial registered
Jan 14, 2016
Incorporation of the first participant
Dec 23, 2016
Recruitment status
Completed
Academic title
(Data source: WHO)
A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid to Investigate Safety and Efficacy of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Type of trial
(Data source: WHO)
Interventional
Design of the trial
(Data source: WHO)
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Phase
(Data source: WHO)
Phase 2
Primary end point
(Data source: WHO)
Progression free survival (PFS) at 6 months assessed by Response Evaluation Criteria in Solid Tumors (RECIST)
Contact information
(Data source: WHO)
Please refer to primary and secondary sponsors
Trial results
(Data source: WHO)
Results summary
no information available yet
Link to the results in the primary register
no information available yet
Information on the availability of individual participant data
no information available yet
Trial sites
Trial sites in Switzerland
(Data source: BASEC)
Lausanne
Countries
(Data source: WHO)
France, Netherlands, Spain, Switzerland, United Kingdom
Contact for further information on the trial
Details of contact in Switzerland
(Data source: BASEC)
Dr. Sarivalasis Apostolos
+41 79 556 73 62
apostolos.sarivalasis@chuv.ch
Contact for general information
(Data source: WHO)
Susana- Banerjee;George Coukos
Royal Marsden Hospital - UK;Centre Hospitalier Universitaire Vaudois - Lausanne
Contact for scientific information
(Data source: WHO)
Susana- Banerjee;George Coukos
Royal Marsden Hospital - UK;Centre Hospitalier Universitaire Vaudois - Lausanne
Authorisation by the ethics committee (Data source: BASEC)
Name of the authorising ethics committee (for multicentre studies only the lead committee)
Commission
cantonale d’Éthique de la Recherche sur l’être humain Vaud (CER-VD)
Date of authorisation by the ethics committee
11.08.2016
Further trial identification numbers
Trial identification number of the ethics committee (BASEC-ID)
(Data source: BASEC)
2016-00776
Secondary ID (Data source: WHO)
2015-004601-17
EORTC-1508
Back to overview